Is Mounjaro safe for people with type 1 diabetes?

Why the licensing decision excluded type 1 diabetes

A common assumption is that because Mounjaro affects blood sugar and appetite, it must work the same way for both types of diabetes. That isn't quite how licensing works. Mounjaro's UK authorisation covers weight management in adults with a BMI of 30 or above (or 27 or above with at least one weight-related condition), and separately as a treatment for type 2 diabetes. Both of those approvals rest on large clinical trial programmes that enrolled tens of thousands of adults with those specific conditions.

Type 1 diabetes is a different disease mechanism. People with type 1 produce little or no insulin of their own and depend on injected insulin to survive. Mounjaro's dual GIP and GLP-1 receptor agonist action slows gastric emptying and reduces appetite, but it does not replace insulin. The NHS medicines information for tirzepatide makes clear that the medicine is not indicated for type 1 diabetes, and the Summary of Product Characteristics does not include this population. That omission is not an oversight, it reflects the absence of adequate trial data, not a promise that it might work.

There is some academic interest in GLP-1 receptor agonists as an adjunct therapy in type 1 diabetes, but the evidence is early-stage and inconclusive. Nothing in that research changes the current UK licensing position, and an Independent Prescriber cannot safely act on theoretical interest alone.

The hypoglycaemia question (the most clinically serious concern

For anyone managing type 1 diabetes with insulin, adding a medicine that further reduces blood glucose could push levels into hypoglycaemia) and that carries real risk. GLP-1 receptor agonists slow the rate at which the stomach empties food into the small intestine, which changes when carbohydrates are absorbed and how quickly blood sugar rises after a meal. Predicting and managing insulin doses against that moving variable is genuinely difficult, and the NHS England guidance on weight-management injections highlights insulin-dose management as a key consideration whenever GLP-1 medicines are used alongside diabetes treatment.

In type 2 diabetes, some insulin is still produced and the risk is modifiable. In type 1, the insulin comes entirely from injections, and no clinical trial data exists to show that Mounjaro can be titrated safely alongside it. That gap in evidence is precisely why the licence does not extend here. It is also why a prescriber (including ours) would not offer Mounjaro to someone with type 1 diabetes as part of a routine weight-loss consultation.

If you want to understand Mounjaro's side-effect profile more broadly, our page on Mounjaro side effects covers what is known from the licensed trials.

What you can do if you have type 1 diabetes and want to manage your weight

Weight management is genuinely important for people with type 1 diabetes, it affects insulin sensitivity, cardiovascular risk and quality of life. The difficulty is that most weight-loss medicines studied in obesity trials either excluded type 1 participants or carry interaction risks that make off-label use inadvisable without specialist oversight.

The most appropriate route is a referral to a specialist weight management service or a diabetes dietitian. Some NHS services can support people with type 1 in structured weight management programmes. Our guide to Mounjaro safety across different diabetes types sets out how the medicine's use differs between type 1 and type 2 in more detail, and our overview of Mounjaro's effects in people with diabetes may help you frame a conversation with your specialist.

If your GP or diabetes team decides that a GLP-1 medicine is appropriate for you in the context of your broader clinical care, they will oversee the prescription and manage the interaction with your existing insulin regimen. That is not something an online pharmacy service (including ours) can do in place of your specialist team.

Who to speak to, and what to ask them

The decision about whether any weight-loss medicine is suitable for someone with type 1 diabetes sits firmly with their diabetes specialist and GP, not with a weight-loss service working from a consultation questionnaire. This is one situation where the nuance of your individual history matters enormously: your current insulin regimen, your HbA1c, any history of hypoglycaemia unawareness, your cardiovascular risk, your weight trajectory. A good starting question for your next appointment is whether there is a specialist weight management pathway that your team can refer you into.

For people without type 1 diabetes who are wondering whether Mounjaro is appropriate for them at all, our page on tirzepatide safety for people without diabetes may be a more relevant starting point, and if you are also curious about how Mounjaro's side effects present specifically in people who don't have diabetes, we cover that in detail too. And if you are already clear that you do not have diabetes and want to explore whether you might be eligible for treatment through a clinically supervised service, you are welcome to speak to our prescribers, they review every consultation personally, the same day, with your full clinical picture in front of them.

The NICE technology appraisal for tirzepatide (TA1026) sets out who the medicine is recommended for in the UK, and our page on whether Mounjaro is safe for weight loss in people without diabetes explains what that means in practice for those who do not have a diabetes diagnosis. Type 1 diabetes does not appear in those recommendations, and until adequately powered clinical trials address the safety questions, that is unlikely to change.